Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
about
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot studyNasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer diseaseT cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.Active and passive immunotherapy for neurodegenerative disordersGlatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of actionSpontaneous fibril formation by polyalanines; discontinuous molecular dynamics simulationsChronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease.Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS.Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders.The double-edged sword of autoimmunity: lessons from multiple sclerosis.Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.The preclinical discovery of amyotrophic lateral sclerosis drugs.Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironmentMotor neuron-immune interactions: the vicious circle of ALS.Therapeutic vaccination for central nervous system repair.Role of immune cells in animal models for inherited peripheral neuropathies.Preclinical trials--an update on translational research in ALS.Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.Current clinical trials in amyotrophic lateral sclerosis.Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.T cells in amyotrophic lateral sclerosis.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyThymic involution, a co-morbidity factor in amyotrophic lateral sclerosis.Guidelines for preclinical animal research in ALS/MND: A consensus meeting.Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Advancing therapeutic options in multiple sclerosis with neuroprotective properties.The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.Effect of glatiramer acetate on short-term memory impairment induced by lipopolysaccharide in male mice.Macrophage migration inhibitory factor as a component of selective vulnerability of motor neurons in ALS.Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteinsThe Role of the Innate Immune System in ALSAcute injury in the peripheral nervous system triggers an alternative macrophage response.Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model.
P2860
Q21034132-456F5191-9011-444C-AE31-5EB20014DCF5Q24534813-7BDAE734-74C6-407E-BAE8-DC40CE9147BDQ24562400-4472414C-EE69-45C3-9D49-5EF938795369Q24657879-58E98AAA-2340-47F1-A3A3-374FC97DE25BQ24676445-4CFA4D9E-DE63-4E71-8FD3-B95D1A0AA44DQ28308287-20198976-7FF8-45BD-8710-9A730BD09D80Q28393682-6D4FD5AC-9FC6-42AE-83B6-DDDBD32FCCF2Q30412083-3A885D62-1E1E-44BC-AB68-18A3DE3BC514Q33354106-A1419A00-BE20-438A-BD89-7624714FB330Q33815568-DD93F94E-4395-4414-93A2-281BA269A814Q33988381-EE7A1A6A-05B6-41C2-B2B6-08CC0AA898CEQ35068792-81C8C498-EEE0-476A-9B98-2B58F0681611Q35155753-860C51F4-2B88-49C2-A5FB-E183BDBF385DQ35607258-FA9D0B97-56AE-4B2F-BA2F-3199F272E6B0Q36009915-CD5506D5-5B38-4EC5-955C-B07B802F6E2CQ36085162-5961BD72-6DAB-4008-8FB1-0FB0A2C9B60EQ36099316-30AAF56D-1481-443E-A0A9-0E84A7520776Q36437332-6908AFCF-DA60-46B6-A93B-89799AF20229Q36478853-9FFCB4B9-CDE4-4986-9FA5-1FF4A4F6AA4BQ36507170-7542A25E-9890-49B3-9719-86F04BC48EF1Q36565682-8698CB18-54BD-476E-886B-1171A89B77C6Q36692860-2CAC4D49-9905-46A0-A159-41C2E6C57569Q36904850-6DAF66F8-4DD3-471B-AE6D-C3799C09335FQ36963184-9308C8A9-2DFA-4976-9188-E3EEB4F8189CQ37081721-F08BC8C9-2998-46B1-8491-76A3ABC596C0Q37280507-E0A2AF53-02CD-41DC-8879-CBBDDF5B3346Q37295387-99F01FC8-024F-41C0-A093-F1768D8BCE5BQ37698628-3F4D167C-61BF-4942-AFB2-11B1BD19BDC6Q37823334-AE300530-7B15-4068-8B23-0ED8CEF312B8Q37997089-38F69638-ECF0-40AD-9CEA-A12BF677606AQ38110475-736CD589-289F-4D0D-BBFE-33C848FA6E2CQ38116543-4DE0A035-A932-4BD3-AB42-28B2C60C10EEQ39809303-1EBB995C-1B60-4058-926C-245099921821Q41596941-8DC0D63E-8FB4-4726-9B81-DDA542EEAFB3Q41825402-D097B7E4-3DCF-4ED0-B99B-AD5CC42C20FCQ41898480-4703C586-DE99-42C8-AAAD-D3BAAC4A3C80Q42276078-F0F046E3-7080-446E-8F94-8BBCAF156CA9Q42908536-DE060DFF-86D6-4745-82D9-F12B978D3A0FQ43239620-4B271FBE-7850-452C-A4B8-7BB09F216CFAQ46093994-04B171D8-38E2-488A-ACA8-AEDAAF2CAC04
P2860
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis
@nl
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@ast
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@en
type
label
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis
@nl
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@ast
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@en
prefLabel
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis
@nl
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@ast
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@en
P2093
P2860
P356
P1476
Therapeutic vaccine for acute ...... amyotrophic lateral sclerosis.
@en
P2093
D N Angelov
M Schwartz
P2860
P304
P356
10.1073/PNAS.0530191100
P407
P577
2003-03-31T00:00:00Z